1. Home
  2. RDHL vs POLA Comparison

RDHL vs POLA Comparison

Compare RDHL & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • POLA
  • Stock Information
  • Founded
  • RDHL 2009
  • POLA 1979
  • Country
  • RDHL Israel
  • POLA United States
  • Employees
  • RDHL N/A
  • POLA N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • POLA Industrial Machinery/Components
  • Sector
  • RDHL Health Care
  • POLA Miscellaneous
  • Exchange
  • RDHL Nasdaq
  • POLA Nasdaq
  • Market Cap
  • RDHL 8.2M
  • POLA 8.3M
  • IPO Year
  • RDHL N/A
  • POLA 2016
  • Fundamental
  • Price
  • RDHL $5.85
  • POLA $2.83
  • Analyst Decision
  • RDHL
  • POLA
  • Analyst Count
  • RDHL 0
  • POLA 0
  • Target Price
  • RDHL N/A
  • POLA N/A
  • AVG Volume (30 Days)
  • RDHL 11.1K
  • POLA 13.2K
  • Earning Date
  • RDHL 04-07-2025
  • POLA 11-14-2024
  • Dividend Yield
  • RDHL N/A
  • POLA N/A
  • EPS Growth
  • RDHL N/A
  • POLA N/A
  • EPS
  • RDHL N/A
  • POLA N/A
  • Revenue
  • RDHL $3,707,000.00
  • POLA $14,953,000.00
  • Revenue This Year
  • RDHL $224.90
  • POLA $6.72
  • Revenue Next Year
  • RDHL $82.69
  • POLA N/A
  • P/E Ratio
  • RDHL N/A
  • POLA N/A
  • Revenue Growth
  • RDHL N/A
  • POLA N/A
  • 52 Week Low
  • RDHL $5.41
  • POLA $2.31
  • 52 Week High
  • RDHL $20.28
  • POLA $4.90
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 40.41
  • POLA 45.18
  • Support Level
  • RDHL $5.80
  • POLA $3.07
  • Resistance Level
  • RDHL $6.26
  • POLA $2.97
  • Average True Range (ATR)
  • RDHL 0.31
  • POLA 0.11
  • MACD
  • RDHL 0.01
  • POLA -0.03
  • Stochastic Oscillator
  • RDHL 19.33
  • POLA 22.22

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About POLA Polar Power Inc.

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications primarily in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, Back-up DC generators, hybrid power systems, Li-Ion battery systems, and Marine DC generators. The Companie's geographical presence is in the United States, Canada, Mexico, South Pacific Islands, Japan, Europe and Middle East and Other Asia Pacific countries.

Share on Social Networks: